Several of our patients are calling with concern about risk of mortality following treatment with Ocrevus. The National MS Society website contains old information suggesting an increased risk of ICU admission in patients treated with Ocrevus who contract COVID-19. Please read this link that was published by Genentech, the makers of Ocrevus. Most notable in this publication is the following statement:
“Our pharmacovigilance data suggests that COVID-19 follows a similar course in ocrelizumab-treated patients with MS as in the general population”. The entire text is below in the attached link. Please feel free to contact our office if you have questions. We at the Multiple Sclerosis Center of Arizona, and the Center for Neurology and Spine are working hard to provide the latest information to our patients regarding treatment of MS during the COVID-19 pandemic.